On August 28, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, announced the successful closing of a public offering, which was upsized to $6.0 million. The offering included the sale of 53,558 American Depositary Shares (ADSs) and associated warrants, as well as pre-funded warrants to purchase additional ADSs. The ADSs and warrants were offered at a price of $1.00 per ADS, with the pre-funded warrants priced at $0.999 each. The warrants are exercisable immediately and will expire one year from the date of issuance, with an exercise price of £0.76 per ADS. The pre-funded warrants can be exercised at any time at a price of $0.001 per ADS. The offering was conducted under a registration statement on Form F-1, which was declared effective...Show More

On August 28, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, announced the successful closing of a public offering, which was upsized to $6.0 million. The offering included the sale of 53,558 American Depositary Shares (ADSs) and associated warrants, as well as pre-funded warrants to purchase additional ADSs. The ADSs and warrants were offered at a price of $1.00 per ADS, with the pre-funded warrants priced at $0.999 each. The warrants are exercisable immediately and will expire one year from the date of issuance, with an exercise price of £0.76 per ADS. The pre-funded warrants can be exercised at any time at a price of $0.001 per ADS. The offering was conducted under a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission (SEC) on the same day. TC BioPharm intends to use the net proceeds to support an upcoming clinical trial for Acute Myeloid Leukemia, increase market awareness, and cover operating expenses and working capital. The company specializes in developing allogeneic gamma-delta T cell therapies for cancer and other indications.